The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only.
 
Sebastian Stintzing
Honoraria - Amgen; Bayer; LEO Pharma; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; Sanofi; Sanofi; SERVIER; Takeda
Research Funding - Merck Serono (Inst); Pierre Fabre (Inst); Roche Molecular Diagnostics (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Lilly; Merck KGaA; Pierre Fabre; Roche; Sanofi; Sirtex Medical; Takeda
 
Ludwig Fischer von Weikersthal
No Relationships to Disclose
 
Martin Fuchs
No Relationships to Disclose
 
Florian Kaiser
No Relationships to Disclose
 
Kathrin Heinrich
Honoraria - Roche Pharma AG
Consulting or Advisory Role - SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Lilly; Merck KGaA; SERVIER
 
Dominik Paul Modest
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Cor2Ed; Incyte; IQvia; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Roche; SERVIER
Research Funding - Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER
 
Ralf-Dieter Hofheinz
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Lilly; Medac; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; Servier
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Lilly; Merck Serono; MSD; Roche; Sanofi; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
Research Funding - German Cancer Aid (Inst); Medac (Inst); Sanofi (Inst)
 
Thomas Decker
Consulting or Advisory Role - Novartis
 
Armin Gerger
No Relationships to Disclose
 
Stefan Angermeier
No Relationships to Disclose
 
Holger Rumpold
No Relationships to Disclose
 
Andreas Dickhut
No Relationships to Disclose
 
Leopold Öhler
No Relationships to Disclose
 
Birgit Gruenberger
No Relationships to Disclose
 
Dora Niedersuess-Beke
No Relationships to Disclose
 
Matthias Sandmann
No Relationships to Disclose
 
Thomas Winder
No Relationships to Disclose
 
Joerg Trojan
No Relationships to Disclose
 
Gerald Prager
No Relationships to Disclose
 
Volker Heinemann
Honoraria - Amgen; AstraZeneca; Merck; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER; Sirtex Medical
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Merck; MSD; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi; Sirtex Medical; TERUMO
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Servier (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Roche; SERVIER; Sirtex Medical